Abstract

Severe hypoglycaemia is a diagnostic challenge.1 It is often explained by mismatch between insulin doses, food ingestion and exercise. Recurrent hypoglycaemia can indicate underlying medical problems. Drug related events usually concern insulin or sulphonylureas. However, withdrawal of drugs which can cause insulin resistance can be causative if insulin or sulphonylureas continue.2We report the case of an insulin-treated patient who presented with severe recurrent hypoglycaemia. After exclusion of secondary causes of hypoglycaemia it was established that at the time of diagnosis of diabetes he had been taking olanzapine. This had subsequently been discontinued. Olanzapine is recognised to cause diabetes and diabetic ketoacidosis. Our patient was able to discontinue insulin therapy.
[download-attachments container="div" style="list" display_icon="1" display_count="1" display__size="0"]

References

1. Cryer PE, Frier BM: Hypoglycaemia, Alberti KGMM, Zimmet P, Defronzo RA, editors: International Textbook of Diabetes Mellitus. 2nd edition. Chichester, 1997, John Wiley & Sons, Ltd.; Volume 2, Chapter. 60, p 1193.
2. Goldstein LE, Sporn J, Brown S, et al; New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999; 40: 5–411.
3. Saleh M, Grunberger M. Hypoglycemia: An Excuse for Poor Glycemic Control? Clinical Diabetes 2001; 19(4): 161–167.
4. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in Diabetes. Diabetes Care 2003; 26(6): 1902–1912.
5. Tattersall RB: Frequency, Causes and Treatment of Hypoglycaemia, Frier BM, Fisher BM, editors: Hypoglycaemia in Clinical Diabetes. Chichester, 1999, John Wiley & Sons, Ltd.; Chapter. 3, p 72.
6. Smith M, Hopkins D, Peveler RC, et al; First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. The British Journal of Psychiatry 2008; 192: 406–411.
7. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. American Diabetes Association. Diabetes Care. 2004; 27 (2): 596–601.
8. Avella JMS, Wetli CV, Wilson JC, et al. Fatal Olanzapine-Induced Hyperglycaemia Ketoacidosis. American Journal of Forensic Medicine and Pathology 2004; 25(2): 172–175.
9. Farwell WR, Stump TE, Wang J, et al; Weight gain and new onset diabetes associated with Olanzapine and Risperidone. Journal of General Internal Medicine 2004; 19: 1200–1205.
10. Sacher J, Mossaheb N, Spindelegger C, et al; Effects of Olanzapine on Healthy Volunteers. Neurophyschopharmacology 2008; 33: 1633–1641.
11. Best L, Yates AP, Reynolds GP. Actions of antipsychotic drugs on pancreatic beta-cell function: contrasting effects of clozapine and haloperidol. J Psychopharmacology 2005; 19(6): 597–601.
12. Breedlove KT. Complete Resolution of Olanzapine-Induced Diabetic Ketoacidosis. Journal of Pharmacy Practice 2006; 19(4): 255–258.
13. Kohen I, Gampel M, Reddy L, et al; Rapidly Developing Hyperglycemia During Treatment with Olanzapine. The Annals of Pharmacotherapy 2008; 42(4): 588–591.